NeuroVive To Take Traumatic Brain Injury Drug Into Mid-Stage Studies
Executive Summary
Protecting the function of mitochondria may be key to developing medicines to reduce the nerve damage caused by traumatic brain injuries. NeuroVive Pharmaceutical is moving its cyclosporine candidate into Phase IIb studies.